Protein / target

Alpha-2A adrenergic receptor

ADRA2AP08913Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
47
Approved medicines
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Alpha-1B adrenergic receptor binding

Primary system

Nervous system

Strongest disease association

asthma

Clinical evidence · score 0.62

Therapeutic maturity

Clinically validated target

47 approved medicines against this target

Druggability

Small molecule

Open Targets tractability · Approved Drug

Clinical development

47 approved · 8 in clinical development

30 linked trials

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate the G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression (PubMed:2170371, PubMed:23105096, PubMed:2568356, PubMed:35245122, PubMed:27376152). Control a variety of physiological processes, such as regulation of blood pressure, lipolysis and insulin release (PubMed:2568356, PubMed:27376152). ADRA2A and ADRA2C mediates the presynaptic feedback inhibition of neurotransmitter release from noradrenergic nerve terminals in sympathetic and central nervous systems. ADRA2A inhibits transmitter release at high stimulation frequencies, whereas ADRA2C modulates neurotransmission at lower levels of nerve activity (By similarity). The rank order of potency for agonists of ADRA2A is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol (PubMed:2170371, PubMed:2568356)

Subcellular location

Cell membrane
Domains and Gene Ontology detail (60)

Gene Ontology

  • Caxon terminus
  • Cbasolateral plasma membrane
  • Ccytoplasm
  • Cdopaminergic synapse
  • CGABA-ergic synapse
  • Cglutamatergic synapse
  • Cneuronal cell body
  • Cplasma membrane
  • Cpostsynaptic density membrane
  • Cpresynaptic active zone membrane
  • Creceptor complex
  • Falpha-1B adrenergic receptor binding

465 aa · 51 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Synaptic signallingUniProt · GOG protein-coupled signallingUniProt · GOKinase signallingGOInhibitory neurotransmissionGOExcitatory neurotransmissionGOImmune signallingGO
View supporting evidence

Synaptic signalling

  • ·Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that act…
  • ·dopaminergic synapse
  • ·GABA-ergic synapse
  • ·glutamatergic synapse

G protein-coupled signalling

  • ·Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that act…
  • ·adenylate cyclase-activating G protein-coupled receptor signaling pathway
  • ·adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway
  • ·G protein-coupled receptor signaling pathway

Kinase signalling

  • ·protein kinase binding
  • ·positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction

Inhibitory neurotransmission

  • ·GABA-ergic synapse

Excitatory neurotransmission

  • ·glutamatergic synapse

Immune signalling

  • ·positive regulation of cytokine production
View underlying pathways (6)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

GNB1GNAQGNAO1GNG2GNA12GNA13GNA11SLC6A3SLC6A2GNB3ADRA2A

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Epinephrine
ApprovedAgonist

Adrenergic receptor agonist

Appears in clinical studies involving sudden cardiac arrest, asthma, sinusitis, septic shock

Acts on a complex — shared with ADRA1A, ADRB2, ADRA1D +5 more · 1 of 9 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Translational evidence

Open Targets 26

Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.

Highest-confidence therapeutic associations

Diseases where a drug acting on this target has already reached clinical development.

major depressive disorder0.99

Clinical · overall 0.61

ocular hypertension0.99

Clinical · overall 0.60

attention deficit-hyperactivity disorder0.98

Clinical · overall 0.61

hypertensive disorder0.98

Clinical · overall 0.60

Nasal congestion0.98

Clinical · overall 0.60

Highest overall evidence

Remaining associations by Open Targets' aggregated evidence score.

asthma0.62

Clinical

open-angle glaucoma0.60

Clinical

glaucoma0.60

Clinical

seasonal allergic rhinitis0.59

Clinical

Pain0.59

Clinical

Show all associations
asthma0.62
attention deficit-hyperactivity disorder0.61
major depressive disorder0.61
hypertensive disorder0.60
ocular hypertension0.60
Nasal congestion0.60
open-angle glaucoma0.60
glaucoma0.60
seasonal allergic rhinitis0.59
Pain0.59

Open Targets ranks 568 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.

Known drugs · 57 total

FADOLMIDINEPhase 2

neuropathic pain · Pain

GUANFACINEApproval

hypertensive disorder · attention deficit-hyperactivity disorder · attention deficit-hyperactivity disorder

EPHEDRINE SULFATEApproval

hypotensive disorder · asthma

HYDROXYAMPHETAMINE HYDROBROMIDEApproval

Horner syndrome

RAUWOLFIA SERPENTINAApproval

hypertensive disorder · essential hypertension

LOFEXIDINEApproval

opiate dependence · drug dependence · cannabis dependence

METHYLDOPATE HYDROCHLORIDEApproval

Hypertension

TETRAHYDROZOLINE HYDROCHLORIDEUnknown
DEXMEDETOMIDINEApproval

Irritability · sedation · congenital heart disease

ERGOTAMINE TARTRATEApproval

Headache · migraine disorder

Tractability

SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Half-life DataPR · Small Molecule BinderOC · Approved Drug

Safety liabilities

decreased body temperaturememory impairmentdecreased blood pressuredecreased noradrenaline release and sympathetic neurotransmissionincreased gastrointestinal motilityincreased convulsionshyperglycemiaanesthetic-sparing effectsedationweight gaindecreased gastric emptyingincreased insulin secretion

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Show remaining trials (24)

ClinicalTrials.gov via the drug-target graph.

Forefront confidence

Synthesis

Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.

asthmaWell supported
0.76
agreement 0.600.92
Clinical88%Literature12%

Open Targets aggregate 0.62 · 2 independent evidence families

attention deficit-hyperactivity disorderWell supported
0.75
agreement 0.600.91
Clinical92%Literature8%

Open Targets aggregate 0.61 · 2 independent evidence families

major depressive disorderWell supported
0.75
agreement 0.590.91
Clinical98%Literature3%

Open Targets aggregate 0.61 · 2 independent evidence families

hypertensive disorderModerately supported
0.74
agreement 0.590.90
Clinical98%Literature2%

Open Targets aggregate 0.60 · 2 independent evidence families

ocular hypertensionModerately supported
0.74
agreement 0.570.91
Clinical100%

Open Targets aggregate 0.60 · 1 independent evidence family

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.

What's happening now

12

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. Label change2026-06-22

    Label change: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

  2. Product recall2026-05-14

    Recall (Class III): EPINEPHRINE

    fda · safety · fda · via Epinephrine

  3. Regulatory approval2024-08-22

    Approval: Eurneffy (EMA)

    ema · regulatory · ema · via Epinephrine

  4. New publication2023-11-07
    Impact of norepinephrine on immunity and oxidative metabolism in sepsis.

    Frontiers in immunology · 2023 · 33 citations · Europe PMC · via Epinephrine

  5. Label change2023-01-05

    Label change: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

  6. Supplemental approval2021-08-17

    Supplemental approval: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

  7. New publication2019-10-31
    The effect of topical epinephrine 1:1000 with and without infiltration of 1% lidocaine with epinephrine 1:100,000 on endoscopic surgical field visualization: a double-blind randomized controlled study.

    International forum of allergy & rhinology · 2020 · 6 citations · Europe PMC · via Epinephrine

  8. Indication expanded2019-01-29

    Indication expansion: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

  9. Label change2017-08-09

    Label change: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

  10. Label change2016-05-18

    Label change: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

  11. Supplemental approval2015-12-23

    Supplemental approval: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

  12. Regulatory approval2013-12-18

    Approval: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.